Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Efficacy, and Safety of rVIIa-FP in Hemophilia A or B with Inhibitors
NCT02484638Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Jul 2015
- Primary completion
- Mar 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of CSL689 in hemophilia A, hemophilia B (HB), sponsored by CSL Limited. Started Jul 2015; status: terminated.
02
Drugs
CSL689
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02484638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02484638.